1
Genome editing is becoming infrastructure, not a single breakthrough
The next race is not only to edit genomes, but to deliver, time and measure biological programs across cells and systems.
Genome editing coverage is no longer just about CRISPR as a technique. Genetic Engineering Publications - GEG Tech top picks frames the field as programmable medicine, with a Nature guide emphasizing newer editors and the delivery problem behind them: getting the right biological program into the right cell for the right duration.
The same topic follows the medical edge of that shift. One post points to in vivo base editing that partly rescues bone dysplasia in a mouse model of Hutchinson-Gilford progeria syndrome. Another follows an off-the-shelf lentiviral vector designed to generate CD19-targeted CAR T cells inside patients with refractory neurological autoimmune disorders.
SynBioFromLeukipposInstitute adds the synthetic biology layer. Posts on bottom-up RNA transfer vehicles and nanosyringes for synthetic cells show that the field is building delivery, sensing and control systems, not only editing enzymes.
RMH brings the molecular readout. A bioRxiv post on a miniature bioluminescent platform for imaging structured RNAs shows the same platform logic at transcript scale, where engineered tags and split luciferase turn RNA behavior into something researchers can watch.
Further reading